Skip to main content
Top
Published in: Virology Journal 1/2020

01-12-2020 | Human Immunodeficiency Virus | Research

Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana

Authors: Billal Musah Obeng, Evelyn Yayra Bonney, Lucy Asamoah-Akuoko, Nicholas Israel Nii-Trebi, Gifty Mawuli, Christopher Zaab-Yen Abana, Kwamena William Coleman Sagoe

Published in: Virology Journal | Issue 1/2020

Login to get access

Abstract

Background

Detection of HIV-1 transmitted drug resistance (TDR) and subtype diversity (SD) are public health strategies to assess current HIV-1 regimen and ensure effective therapeutic outcomes of antiretroviral therapy (ART) among HIV-1 patients. Globally, limited data exist on TDR and SD among blood donors. In this study, drug resistance mutations (DRMs) and SD amongst HIV-1 sero-positive blood donors in Accra, Ghana were characterized.

Methods

Purposive sampling method was used to collect 81 HIV sero-positive blood samples from the Southern Area Blood Center and confirmed by INNO-LIA as HIV-1 and/or HIV-2. Viral RNA was only extracted from plasma samples confirmed as HIV-1 positive. Complementary DNA (cDNA) was synthesized using the RNA as a template and subsequently amplified by nested PCR with specific primers. The expected products were verified, purified and sequenced. Neighbour-joining tree with the Kimura’s 2-parameter distances was generated with the RT sequences using Molecular Evolutionary Genetic Analysis version 6.0 (MEGA 6.0).

Results

Out of the 81 plasma samples, 60 (74%) were confirmed as HIV-1 sero-positive by INNO-LIA HIVI/II Score kit with no HIV-2 and dual HIV-1/2 infections. The remaining samples, 21 (26%) were confirmed as HIV sero-negative. Of the 60 confirmed positive samples, (32) 53% and (28) 47% were successfully amplified in the RT and PR genes respectively. Nucleotide sequencing of amplified samples revealed the presence of major drug resistance mutations in two (2) samples; E138A in one sample and another with K65R. HIV-1 Subtypes including subtypes A, B, CRF02_AG and CRF09_cpx were found.

Conclusion

This study found major drug resistance mutations, E138A and K65R in the RT gene that confer high level resistance to most NNRTIs and NRTI respectively. CRF02_AG was most predominant, the recorded percentage of subtype B and the evolutionary relationship inferred by phylogenetic analysis may suggest possible subtype importation. However, a more prospective and detailed analysis is needed to establish this phenomenon. The data obtained would inform the selection of drugs for ART initiation to maximize therapeutic options in drug-naïve HIV-1 patients in Ghana.
Literature
4.
go back to reference Kiptoo M, Brooks J, Lihana RW, Sandstrom P, Ng’ang’a Z, Kinyua J, et al. HIV-1 drug resistance-associated mutations among HIV-1 infected drug-naïve antenatal clinic attendees in rural Kenya. BMC Infect Dis. 2013;13:517.CrossRef Kiptoo M, Brooks J, Lihana RW, Sandstrom P, Ng’ang’a Z, Kinyua J, et al. HIV-1 drug resistance-associated mutations among HIV-1 infected drug-naïve antenatal clinic attendees in rural Kenya. BMC Infect Dis. 2013;13:517.CrossRef
5.
go back to reference Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with human immunodeficiency virus infection: HIV outpatient study investigators. N Engl J Med. 1998;338:853–60.CrossRef Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with human immunodeficiency virus infection: HIV outpatient study investigators. N Engl J Med. 1998;338:853–60.CrossRef
6.
go back to reference Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro M, et al. The prevalence of antiretroviraldrug resistance in the United States. AIDS. 2004;18:1393–401.CrossRef Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro M, et al. The prevalence of antiretroviraldrug resistance in the United States. AIDS. 2004;18:1393–401.CrossRef
7.
go back to reference Hamers RL. Transmitted HIV-1 drug resistance in Africa. Lusaka: 8th INTEREST workshop; 2014. Hamers RL. Transmitted HIV-1 drug resistance in Africa. Lusaka: 8th INTEREST workshop; 2014.
8.
go back to reference Wittkop L, Gunthard HF, De Wolf F, Dunn D, Cozzi-Lepri A, De Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–71.CrossRef Wittkop L, Gunthard HF, De Wolf F, Dunn D, Cozzi-Lepri A, De Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–71.CrossRef
10.
go back to reference Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174–80.CrossRef Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174–80.CrossRef
11.
go back to reference Wensing AM, Van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management, SPREAD Programme. J Infect Dis. 2005;192:958–66.CrossRef Wensing AM, Van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management, SPREAD Programme. J Infect Dis. 2005;192:958–66.CrossRef
12.
go back to reference Sagoe KWC, Dwidar M, Lartey M, Boamah I, Agyei AA, et al. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana. J Clin Virol. 2007;40:163–7.CrossRef Sagoe KWC, Dwidar M, Lartey M, Boamah I, Agyei AA, et al. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naive patients in Accra, Ghana. J Clin Virol. 2007;40:163–7.CrossRef
13.
go back to reference Brandful JAM, Candotti D, Allain J-P. Genotypic diversity and mutation profile of HIV-1 strains in antiretroviral treatment (ART) –Naïve Ghanaian patients and implications for antiretroviral treatment (ART). J AIDS HIV Res. 2012;4(7):187–97.CrossRef Brandful JAM, Candotti D, Allain J-P. Genotypic diversity and mutation profile of HIV-1 strains in antiretroviral treatment (ART) –Naïve Ghanaian patients and implications for antiretroviral treatment (ART). J AIDS HIV Res. 2012;4(7):187–97.CrossRef
14.
go back to reference Bonney EY, Ntim NAA, Addo-Yobo F, Bondzie P, Aryee KE, Barnor JS, et al. Low level of transmitted HIV drug resistance at two HIV care Centres in Ghana: a threshold survey. Ghana Med J. 2013;47(2):82–6.PubMedPubMedCentral Bonney EY, Ntim NAA, Addo-Yobo F, Bondzie P, Aryee KE, Barnor JS, et al. Low level of transmitted HIV drug resistance at two HIV care Centres in Ghana: a threshold survey. Ghana Med J. 2013;47(2):82–6.PubMedPubMedCentral
15.
go back to reference Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JAM, Ofori SB, et al. HIV-1 drug-resistance surveillance among treatment-experienced and treatment-Naıve patients after the implementation of antiretroviral therapy in Ghana. PLoS One. 2013;8:1–8.CrossRef Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JAM, Ofori SB, et al. HIV-1 drug-resistance surveillance among treatment-experienced and treatment-Naıve patients after the implementation of antiretroviral therapy in Ghana. PLoS One. 2013;8:1–8.CrossRef
17.
go back to reference Villahermosa ML, Thomson M, Vázquez de Parga E, Cuevas MT, Contreras G, Pérez-Alvarez L, et al. Improved conditions for extraction and amplificationof human immunodeficiency virus type 1RNA from plasma samples with low viral load. J Hum Virol. 2000;3(1):27–34.PubMed Villahermosa ML, Thomson M, Vázquez de Parga E, Cuevas MT, Contreras G, Pérez-Alvarez L, et al. Improved conditions for extraction and amplificationof human immunodeficiency virus type 1RNA from plasma samples with low viral load. J Hum Virol. 2000;3(1):27–34.PubMed
18.
go back to reference Fujisaki S, Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, et al. Performance and quality assurance of genotypic drug-resistant testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis. 2007;60:113–7.PubMed Fujisaki S, Fujisaki S, Ibe S, Asagi T, Itoh T, Yoshida S, et al. Performance and quality assurance of genotypic drug-resistant testing for human immunodeficiency virus type 1 in Japan. Jpn J Infect Dis. 2007;60:113–7.PubMed
19.
go back to reference Nii-Trebi NI, Barnor JS, Obeng BM, Ampofo WK. Epidemiologic dominance of HIV-1 subtype CRF02_AG in Ghana: preliminary virological evidence of increasing association with new infections. Int J Virol Stud Res. 2016;4:22–8. Nii-Trebi NI, Barnor JS, Obeng BM, Ampofo WK. Epidemiologic dominance of HIV-1 subtype CRF02_AG in Ghana: preliminary virological evidence of increasing association with new infections. Int J Virol Stud Res. 2016;4:22–8.
20.
go back to reference Fischetti L, Opare-Sem O, Candotti D, Lee H, Allain J-P. Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana. AIDS. 2004;18:1208–10.CrossRef Fischetti L, Opare-Sem O, Candotti D, Lee H, Allain J-P. Higher viral load may explain the dominance of CRF02_AG in the molecular epidemiology of HIV in Ghana. AIDS. 2004;18:1208–10.CrossRef
21.
go back to reference Haddad M, Napolitano LA, Paquet AC, Evans MD, Petropoulos CJ, Whitcomb J, et al. Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility. Antivir Ther. 2011;16:A18. Haddad M, Napolitano LA, Paquet AC, Evans MD, Petropoulos CJ, Whitcomb J, et al. Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility. Antivir Ther. 2011;16:A18.
22.
go back to reference Tambuyzer L, Nijs S, Daems B, Picchi G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr. 2011;58:18–22.CrossRef Tambuyzer L, Nijs S, Daems B, Picchi G, Vingerhoets J. Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine. J Acquir Immune Defic Syndr. 2011;58:18–22.CrossRef
23.
go back to reference Martin-Odoom A, Adiku T, Delgado E, Lartey M, Ampofo WK. Occurrence of transmitted HIV-1 drug resistance among drug-naïve pregnant women in selected HIV care centers in Ghana. Ghana Med J. 2017;51:20–3.CrossRef Martin-Odoom A, Adiku T, Delgado E, Lartey M, Ampofo WK. Occurrence of transmitted HIV-1 drug resistance among drug-naïve pregnant women in selected HIV care centers in Ghana. Ghana Med J. 2017;51:20–3.CrossRef
24.
go back to reference Stephan C, Dauer B, Bickel M, Haberl A, Locher L, Muller A. Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of re-sensitizing mutations including K65R. J Infect. 2010;61:346–50.CrossRef Stephan C, Dauer B, Bickel M, Haberl A, Locher L, Muller A. Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of re-sensitizing mutations including K65R. J Infect. 2010;61:346–50.CrossRef
25.
go back to reference Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59:1047–56.CrossRef Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59:1047–56.CrossRef
26.
go back to reference Mamadou S, Montavon C, Ben A, Djibo A, Rabiou S, M’Boup S, et al. Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. AIDS Res Hum Retrovirus. 2002;18:723–6.CrossRef Mamadou S, Montavon C, Ben A, Djibo A, Rabiou S, M’Boup S, et al. Predominance of CRF02-AG and CRF06-cpx in Niger, West Africa. AIDS Res Hum Retrovirus. 2002;18:723–6.CrossRef
27.
go back to reference Njai HF, Gali Y, Vanham G. The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in west Central Africa may be related to its replicative fitness. Retrovirol. 2006;3:40.CrossRef Njai HF, Gali Y, Vanham G. The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in west Central Africa may be related to its replicative fitness. Retrovirol. 2006;3:40.CrossRef
28.
go back to reference Louwagie J, Delwart EL, Mullins JI, McCutchan FE, Eddy G, Burke DS. Genetic analysis of HIV-1 isolates from Brazil reveals the presence of two distinct genotypes. AIDS Res Hum Retrovirus. 1994;10:561–7.CrossRef Louwagie J, Delwart EL, Mullins JI, McCutchan FE, Eddy G, Burke DS. Genetic analysis of HIV-1 isolates from Brazil reveals the presence of two distinct genotypes. AIDS Res Hum Retrovirus. 1994;10:561–7.CrossRef
29.
go back to reference Louwagie J, Janssens W, Mascola J, Heyndrickx L, Hegerich P, McCutchan FE, et al. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of african origin. J Virol. 1995;69:263–71.CrossRef Louwagie J, Janssens W, Mascola J, Heyndrickx L, Hegerich P, McCutchan FE, et al. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of african origin. J Virol. 1995;69:263–71.CrossRef
30.
go back to reference Deroo S, Robert I, Fontaine E, Lambert C, Plesseria JM, Arendt V, et al. HIV-1 subtypes in Luxembourg, 1983-2000. AIDS. 2002;16:2461–7.CrossRef Deroo S, Robert I, Fontaine E, Lambert C, Plesseria JM, Arendt V, et al. HIV-1 subtypes in Luxembourg, 1983-2000. AIDS. 2002;16:2461–7.CrossRef
31.
go back to reference Tatt ID, Barlow KL, Clewley JP, Gill ON, Parry JV. Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J Acquir Immune Defic Syndr. 2004;36:1096–9.CrossRef Tatt ID, Barlow KL, Clewley JP, Gill ON, Parry JV. Surveillance of HIV-1 subtypes among heterosexuals in England and Wales, 1997-2000. J Acquir Immune Defic Syndr. 2004;36:1096–9.CrossRef
32.
go back to reference Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis. 2011;11:45–56.CrossRef Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis. 2011;11:45–56.CrossRef
33.
go back to reference Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 2012;18:182–92.CrossRef Hemelaar J. The origin and diversity of the HIV-1 pandemic. Trends Mol Med. 2012;18:182–92.CrossRef
Metadata
Title
Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana
Authors
Billal Musah Obeng
Evelyn Yayra Bonney
Lucy Asamoah-Akuoko
Nicholas Israel Nii-Trebi
Gifty Mawuli
Christopher Zaab-Yen Abana
Kwamena William Coleman Sagoe
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2020
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-020-01386-y

Other articles of this Issue 1/2020

Virology Journal 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.